MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

Search

BioCryst Pharmaceuticals Inc

Închisă

SectorSănătate

8.69 1.16

Rezumat

Modificarea prețului

24h

Curent

Minim

8.44

Maxim

8.71

Indicatori cheie

By Trading Economics

Venit

27M

32K

Vânzări

14M

146M

Marjă de profit

0.022

Angajați

580

EBITDA

22M

21M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+94.99% upside

Dividende

By Dow Jones

Următoarele câștiguri

4 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

23M

1.9B

Deschiderea anterioară

7.53

Închiderea anterioară

8.69

BioCryst Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 iul. 2025, 23:34 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 iul. 2025, 21:14 UTC

Achiziții, Fuziuni, Preluări

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 iul. 2025, 21:04 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 iul. 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 iul. 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 iul. 2025, 22:47 UTC

Achiziții, Fuziuni, Preluări

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 iul. 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 iul. 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 iul. 2025, 22:43 UTC

Achiziții, Fuziuni, Preluări

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 iul. 2025, 22:43 UTC

Achiziții, Fuziuni, Preluări

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 iul. 2025, 22:40 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 iul. 2025, 22:40 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 iul. 2025, 22:30 UTC

Market Talk
Câștiguri

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 iul. 2025, 22:20 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

17 iul. 2025, 22:20 UTC

Market Talk
Câștiguri

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 iul. 2025, 22:04 UTC

Market Talk
Câștiguri

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 iul. 2025, 22:03 UTC

Achiziții, Fuziuni, Preluări

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 iul. 2025, 21:58 UTC

Market Talk
Câștiguri

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 iul. 2025, 21:57 UTC

Câștiguri

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 iul. 2025, 21:47 UTC

Câștiguri

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 iul. 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 iul. 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 iul. 2025, 21:38 UTC

Achiziții, Fuziuni, Preluări

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 iul. 2025, 21:22 UTC

Achiziții, Fuziuni, Preluări

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 iul. 2025, 21:05 UTC

Câștiguri

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 iul. 2025, 21:04 UTC

Achiziții, Fuziuni, Preluări

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 iul. 2025, 21:02 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 iul. 2025, 20:59 UTC

Achiziții, Fuziuni, Preluări

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

17 iul. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

BioCryst Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

94.99% sus

Prognoză pe 12 luni

Medie 16.75 USD  94.99%

Maxim 30 USD

Minim 11 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBioCryst Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

11

Cumpărare

1

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.